Article Contents ::
- 1 The Brand Name METHOD Has Generic Salt :: METHYLPHENIDATE
- 2 METHOD Is From Company Intas Priced :: Rs. 132
- 3 METHOD have METHYLPHENIDATE is comes under Sub class Nootropics , Neurotonics,Stimulants of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Nootropics , Neurotonics,Stimulants
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name METHOD Has Generic Salt :: METHYLPHENIDATE
METHOD Is From Company Intas Priced :: Rs. 132
METHOD have METHYLPHENIDATE is comes under Sub class Nootropics , Neurotonics,Stimulants of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Nootropics , Neurotonics,Stimulants
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| METHYLPHENIDATE | TAB | Rs. 132 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| METHOD | Intas | 20MG | 10 | Rs. 132 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Intas :: METHOD | METHYLPHENIDATE | Nervous System | Nootropics , Neurotonics,Stimulants |
Indications for Drugs ::
Narcolepsy, Hyperactivity disorders
Drug Dose ::
Adult: PO Narcolepsy 20-30 mg/day in divided doses. Effective range: 10-60 mg/day.
Contraindication ::
Marked anxiety, tension, agitation; glaucoma; Tourette’s syndrome or tics. Known severe structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac disorders that could increase the risk of sudden death. Extended-release form: Severe hypertension, heart failure, arrhythmia, hyperthyroidism, recent MI or angina.
Drug Precautions ::
Pregnancy and lactation. History of alcohol or drug abuse. Hypertension and other CV disorders that might be exacerbated by increases in BP or heart rate. Pre-existing psychosis or bipolar disorder; monitor for symptoms of aggression or hostility. History of seizure disorder. Children <6 yr (growth suppression); monitor growth during therapy. May impair ability to drive or operate machinery. Transdermal: Avoid exposure of application site to any direct external heat source Drug Side Effects ::
Angina, arrhythmia, cerebral arteritis, cerebral occlusion, changes in BP, MI, necrotising vasculitis, palpitation, pulse changes, tachycardia; depression, dizziness, drowsiness, fever, headache, insomnia, nervousness, neuroleptic malignant syndrome (NMS), Tourette’s syndrome, toxic psychosis; erythema multiforme, exfoliative dermatitis, hair loss, rash, urticaria; growth retardation; abdominal pain, anorexia, diarrhoea, nausea, vomiting, weight loss; anaemia, leukopenia, thrombocytopenic purpura, thrombocytopenia; abnormal LFTs, hepatic coma, increased transaminases; arthralgia, dyskinesia; blurred vision, visual accommodation disturbance; cough, pharyngitis, sinusitis, upper respiratory tract infection; accidental injury, hypersensitivity. Transdermal: Insomnia, decreased appetite; nausea; tic, emotional instability; vomiting, anorexia; nasal congestion, nasopharyngitis; weight loss.
Pregnancy category ::
3
Drug Mode of Action ::
Methylphenidate is a central stimulant and indirect-acting sympathomimetic.
Drug Interactions ::
May reduce effects of antihypertensive agents. Reduced serum level with carbamazepine. Increased serum levels or effects with CYP2D6 inhibitors e.g. chlorpromazine, delavirdine, fluoxetine, miconazole, paroxetine, pergolide, quinidine, quinine, ritonavir, ropinirole. May increase serum levels of phenytoin, TCAs. Possible severe hypertension and tachycardia with sibutramine. CNS depression with alcohol. Potentially Fatal: Severe toxic reactions with clonidine. Increased risk of hypertensive crisis with MAOIs.
